Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
McKesson (NYSE:MCK) reported a strong fiscal third quarter with double-digit growth in revenue and adjusted EPS.
The company expanded its oncology, biopharma services, and North American pharmaceutical distribution operations during the quarter.
Management raised full-year earnings guidance and highlighted progress toward separating the medical-surgical business, including transition service agreements.
McKesson is preparing for a potential IPO of the medical-surgical unit while integrating acquisitions such as Florida Cancer Specialists and Prism Vision.
McKesson sits at the center of the pharmaceutical supply chain, connecting drug manufacturers, providers, and pharmacies. For readers watching healthcare distribution and services, this mix of oncology growth, biopharma services expansion, and core North American distribution activity helps explain why the latest quarter is getting attention. The company is also reshaping its business mix by moving its medical-surgical segment toward a stand-alone path.
For investors, key threads to watch include how the separation of the medical-surgical business develops, how smoothly the new acquisitions are integrated, and how technology and services investments affect margins over time. Together, these moves may influence how McKesson’s earnings are composed and which parts of the business drive most of the value in the future.
Stay updated on the most important news stories for McKesson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on McKesson.
NYSE:MCK 1-Year Stock Price Chart
Why McKesson could be great value
✅ Price vs Analyst Target: The current price of US$822 sits about 13% below the US$945 analyst target.
✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading about 41.3% below the estimated fair value.
❌ Recent Momentum: The 30 day return is about 0.35% lower, so the stock has not had short term strength.
Check out Simply Wall St’s in depth valuation analysis for McKesson.
📊 The strong quarter, higher earnings outlook, and progress on the medical surgical separation all contribute to how durable current earnings look at this price.
📊 Watch how oncology and biopharma services contribute to revenue and margins, and whether integration of recent acquisitions supports the upgraded guidance.
⚠️ The company carries a high level of debt, so you may want to see how cash flows and any separation related costs affect balance sheet flexibility.
For the full picture including more risks and rewards, check out the complete McKesson analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MCK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com